شرح

A rare disease, also referred to as an orphan disease, is any disease that affects a small percentage of the population. There are thousands of rare diseases. To date, six to seven thousand rare diseases have been discovered and new diseases are regularly described in medical literature. The global rare disease diagnostics market in terms of revenue is set to grow by US$ 12 میلیارد در طول 2021-2027, رشد با نرخ رشد مرکب سالانه (CAGR) از 8.6% در طول دوره پیش بینی, بر اساس داده ها و شرکت تحلیلی StrategyHelix. Rising burden of diseases and increase in incidence and prevalence of genetic disorders and various types of cancer, increase in adoption of whole genome and exome sequencing, and increasing research funding and surge in usage for new techniques are driving market growth.

این گزارش داده های به روز اندازه بازار را برای دوره ارائه می دهد 2017-2020 و پیش بینی به 2027 covering key market aspects like sales value for rare disease diagnostics. The global rare disease diagnostics market is segmented on the basis of disease, فن آوری, age, analysis target, و منطقه. By disease, it is categorized into cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases. The diagnostics for rare cancers segment held the largest market share in 2020. By technology, the rare disease diagnostics market is divided into polymerase chain reaction (PCR), next-generation sequencing, microarrays, و دیگران. Based on age, the rare disease diagnostics market is divided into children, and adult. Rare disease diagnostics market by analysis target is divided into multiple genes, whole exome, single genes, and whole genome.

The report has profiled some of the key players of the market such as 3billion Inc., Agilent Technologies Inc., BGI Group, Centogene AG, Eurofins Scientific SE, Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer Inc., Quest Diagnostics Incorporated.

این گزارش منبع ارزشمندی برای شرکت ها و سازمان های فعال در این صنعت است. It provides a cohesive picture of the rare disease diagnostics market to help drive informed decision making for industry executives, سیاست گذاران, علمی, و تحلیلگران.

دامنه گزارش

Disease: cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases
فن آوری: polymerase chain reaction (PCR), next-generation sequencing, microarrays, و دیگران
Age: children, and adult
منطقه: آمریکای شمالی, آسیا و اقیانوسیه, اروپا, و بقیه جهان (ROW)
Analysis target: multiple genes, whole exome, single genes, and whole genome
سال های در نظر گرفته شده: این گزارش دوره را پوشش می دهد 2017 به 2027

مزایای کلیدی برای ذینفعان

Get a comprehensive picture of the global rare disease diagnostics market
شناسایی استراتژی های منطقه ای و اولویت های استراتژیک بر اساس داده ها و تحلیل های محلی
بخش های رشد و روند سرمایه گذاری را مشخص کنید
Understand what the future of the global rare disease diagnostics market looks like
چشم انداز رقابتی و پنجره فرصت را شناسایی کنید

فهرست مطالب

1. تعریف بازار
2. روش تحقیق
3. داده های بازار & چشم انداز
3.1 ارزش بازار
3.2 پیش بینی ارزش بازار
4. Rare Disease Diagnostics Market by Disease
4.1 Cardiovascular
4.2 Central Nervous System
4.3 Endocrine And Metabolic
4.4 Hematology
4.5 Immune And Inflammation
4.6 Rare Cancers
4.7 Other Diseases
5. Rare Disease Diagnostics Market by Technology
5.1 Polymerase Chain Reaction (Pcr)
5.2 Next-Generation Sequencing
5.3 Microarrays
5.4 دیگران
6. Rare Disease Diagnostics Market by Age
6.1 فرزندان
6.2 بالغ
7. Rare Disease Diagnostics Market by Analysis Target
7.1 Multiple Genes
7.2 Whole Exome
7.3 Single Genes
7.4 Whole Genome
8. Rare Disease Diagnostics Market by Region
8.1 آمریکای شمالی
8.2 آسیا و اقیانوسیه
8.3 اروپا
8.4 بقیه دنیا (ردیف)
9. مشخصات شرکت
9.1 3billion Inc.
9.2 Agilent Technologies Inc.
9.3 BGI Group
9.4 Centogene AG
9.5 Eurofins Scientific SE
9.6 Illumina Inc.
9.7 Invitae Corporation
9.8 Laboratory Corporation of America Holdings
9.9 PerkinElmer, شرکت.
9.10 Quest Diagnostics Incorporated
10. ضمیمه
10.1 درباره StrategyHelix
10.2 سلب مسئولیت